Who is the CEO of Bristol-Myers Squibb?

Christopher S. Boerner, Ph.D, since 2023, as the AsOf record states with its sources.

Record

Bristol-Myers Squibb as of November 9, 2026 · AsOf

organization

Bristol-Myers Squibb

Bristol-Myers Squibb is an American pharmaceutical company, headquartered in Princeton. Its CEO is Christopher S. Boerner, Ph.D, since 2023. It reported revenue of $48.19B for the period ended December 31, 2025.

CEO: Christopher S. Boerner, Ph.D since 2023 sec.gov
CFO: David V. Elkins sec.gov
Headquarters: Princeton sec.gov
Revenue: $48.19B to 2025-12-31 sec.gov
Ticker: BMY · NYSE sec.gov

Read the record as of a date

State as of 2026-11-09

8 assertedThe record stands behind this value for the day asked: two independent sources agree, or a primary source states it (alone, at confidence 0.7 or more). Everything else stays on the record, labelled.More in About → facts

Bristol-Myers Squibb: state as of 2026-11-09, one row per fact with its value, date, confidence and sources
fact	value	valid fromThe day the value took effect, not the day it was published. A period figure (a year's revenue) is dated at the period's end.More in About →	confidenceHow well the sources support the value, from 0 to 1. A single primary source is asserted from 0.7; nothing below 0.5 is asserted; a dead or disagreeing source lowers it.More in About →	sourcesPrimary: the entity's own filing, feed or site. Secondary: a publisher reporting it. Each claim links every source it has, with the passage that states the value where one was read.

Latest

0 dated events · full timeline →

No dated events on the record yet.

Releases, deals, appointments and policy changes land here once a checked source dates them.

Every claim on the timeline, including undated ones →

Financials

latest period on record · change vs prior year

Revenue

$48.19B

2025-12-31-0.2%

every revenue figure →

Net income

$7.05B

2025-12-31+178.8%

every net income figure →

Total assets

$88.77B

2026-09-30-8.4%

Cash

$9.57B

2026-09-30-39.1%

As reported in the linked filings, which may be restated. Not investment advice.

State changes since 2026-05-13

21 changes · supersededA later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.More in About →

2026-10-21 · shares outstandingshares outstanding

sec.gov: 1 source for shares outstanding, claim clm_434253DF3386

2026-07-22 · shares outstandingshares outstanding

sec.gov: 1 source for shares outstanding, claim clm_5166F8F7F132 replaced by →

2026-09-30 · quarterly net incomequarterly net income

About this record

Identifiers9 keys · schema.org snippet

AsOf ID: ent_bristol-myers-squibb
Wikidata: Q266423
X: bmsnews
website: www.bms.com
SEC CIK: 0000014272
fiscal year end: 12-31
SIC industry: Pharmaceutical Preparations (2834)
incorporated in: DE
ticker: BMY

Cite this record in schema.org

"sameAs": ["https://www.wikidata.org/wiki/Q266423", "https://asof.is/record/bristol-myers-squibb"],
"identifier": { "@type": "PropertyValue", "propertyID": "asof", "value": "ent_bristol-myers-squibb" }

Paste into the entity's JSON-LD. Why and how.

Sources on this entity2 sites · 528 citations

sec.govprimary · 526

528 claims on record, 25 currently valid, 503 superseded. Last change 2026-10-21.

Chair	Christopher S. Boerner, Ph.D 2024-04-01sec.gov: 1 source for Chair, claim clm_62358F2F8937	2024-04-01	0.95	sec.gov: 1 source for Chair, claim clm_62358F2F8937
quarterly net income	2,162,000,000 United States dollar 2026-09-30sec.gov: 1 source for quarterly net income, claim clm_247D46C4A3C2	2026-09-30	0.95	sec.gov: 1 source for quarterly net income, claim clm_247D46C4A3C2
quarterly operating income	1,402,000,000 United States dollar 2012-03-31sec.gov: 1 source for quarterly operating income, claim clm_B92B3F0BD51E	2012-03-31	0.95	sec.gov: 1 source for quarterly operating income, claim clm_B92B3F0BD51E
quarterly research and development	2026-09-30sec.gov: 1 source for quarterly research and development, claim clm_F9CEFB4CA8DE	2026-09-30	0.95	sec.gov: 1 source for quarterly research and development, claim clm_F9CEFB4CA8DE
quarterly revenue	2026-09-30sec.gov: 1 source for quarterly revenue, claim clm_41E4C7C8DCE2	2026-09-30	0.95	sec.gov: 1 source for quarterly revenue, claim clm_41E4C7C8DCE2
research and development	2025-12-31sec.gov: 1 source for research and development, claim clm_1D1D9926921B	2025-12-31	0.95	sec.gov: 1 source for research and development, claim clm_1D1D9926921B
shares outstanding	2026-10-21sec.gov: 1 source for shares outstanding, claim clm_434253DF3386	2026-10-21	0.95	sec.gov: 1 source for shares outstanding, claim clm_434253DF3386
total equity	2026-09-30sec.gov: 1 source for total equity, claim clm_724BB1A9B7DC	2026-09-30	0.95	sec.gov: 1 source for total equity, claim clm_724BB1A9B7DC